CA2787783A1 - Anti-ilt5 antibodies and ilt5-binding antibody fragments - Google Patents

Anti-ilt5 antibodies and ilt5-binding antibody fragments Download PDF

Info

Publication number
CA2787783A1
CA2787783A1 CA2787783A CA2787783A CA2787783A1 CA 2787783 A1 CA2787783 A1 CA 2787783A1 CA 2787783 A CA2787783 A CA 2787783A CA 2787783 A CA2787783 A CA 2787783A CA 2787783 A1 CA2787783 A1 CA 2787783A1
Authority
CA
Canada
Prior art keywords
seq
ilt5
antibody
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2787783A
Other languages
English (en)
French (fr)
Inventor
Irina Apostolou
Paul Ponath
Joe Ponte
Michael Rosenzweig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
TolerRx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TolerRx Inc filed Critical TolerRx Inc
Publication of CA2787783A1 publication Critical patent/CA2787783A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2787783A 2010-01-20 2011-01-20 Anti-ilt5 antibodies and ilt5-binding antibody fragments Abandoned CA2787783A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29679110P 2010-01-20 2010-01-20
US61/296,791 2010-01-20
PCT/US2011/021939 WO2011091177A1 (en) 2010-01-20 2011-01-20 Anti-ilt5 antibodies and ilt5-binding antibody fragments

Publications (1)

Publication Number Publication Date
CA2787783A1 true CA2787783A1 (en) 2011-07-28

Family

ID=44307212

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2787783A Abandoned CA2787783A1 (en) 2010-01-20 2011-01-20 Anti-ilt5 antibodies and ilt5-binding antibody fragments

Country Status (6)

Country Link
US (2) US9023997B2 (cg-RX-API-DMAC7.html)
EP (1) EP2525813B1 (cg-RX-API-DMAC7.html)
JP (1) JP2013517330A (cg-RX-API-DMAC7.html)
AU (1) AU2011207253B2 (cg-RX-API-DMAC7.html)
CA (1) CA2787783A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011091177A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3623473A1 (en) 2005-03-31 2020-03-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
KR101463631B1 (ko) 2006-03-31 2014-11-19 추가이 세이야쿠 가부시키가이샤 항체의 혈중 동태를 제어하는 방법
RU2510400C9 (ru) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
PH12021552811A1 (en) 2007-09-26 2022-11-21 Chugai Pharmaceutical Co Ltd Modified antibody constant region
EP3674317B1 (en) 2009-03-19 2024-12-11 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
US8846397B2 (en) * 2010-01-20 2014-09-30 Merck Sharp & Dohme Corp. Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
EP2813568B1 (en) 2012-02-09 2025-04-23 Chugai Seiyaku Kabushiki Kaisha Modified fc region of antibody
US20150174203A1 (en) * 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
US10097315B2 (en) * 2013-04-19 2018-10-09 Qualcomm Incorporated Group scheduling and acknowledgement for wireless transmission
ES2881306T3 (es) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
US9985802B2 (en) * 2014-10-31 2018-05-29 Qualcomm Incorporated Channel estimation enhancements
WO2016127247A1 (en) * 2015-02-11 2016-08-18 University Health Network Methods and compositions for modulating lilr proteins
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
BR112018009312A8 (pt) 2015-12-28 2019-02-26 Chugai Pharmaceutical Co Ltd método para promover eficiência de purificação de polipeptídeo contendo região de fc
US11787858B2 (en) 2016-12-22 2023-10-17 Icahn School Of Medicine At Mount Sinai Anti-LILRB3 antibodies and methods of use thereof
SG11202100096XA (en) 2018-07-09 2021-02-25 Five Prime Therapeutics Inc Antibodies binding to ilt4
EP3911680A4 (en) 2019-01-18 2022-09-07 University Health Network LILRB3 BINDING MOLECULES AND ASSOCIATED USES
WO2020196926A1 (ja) * 2019-03-28 2020-10-01 学校法人早稲田大学 細胞競合の制御剤
CN115175940A (zh) * 2020-02-12 2022-10-11 生物发明国际公司 Lilrb3抗体分子及其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61122292A (ja) 1984-11-16 1986-06-10 Teijin Ltd 新規カルバサイクリン中間体の製法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1097945B1 (en) 1991-03-18 2007-07-04 New York University Monoclonal and chimeric antibody specific for human tumor necrosis factor
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
EP0614984B2 (en) 1993-03-05 2010-11-03 Bayer HealthCare LLC Anti-TNF alpha human monoclonal antibodies
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6448035B1 (en) 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
US20060078564A1 (en) * 2002-05-08 2006-04-13 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
EP1261735A4 (en) 2000-01-25 2005-04-06 Nuvelo Inc METHODS AND MATERIALS RELATING TO POLYPEPTIDES AND POLYNUCLEOTIDES LIKE IMMUNOGLOBULIN-LIKE LEUKOCYTE RECEPTORS (LIR)
AU2001239955A1 (en) 2000-02-28 2001-09-12 Hyseq, Inc. Novel macrophage nucleic acids and polypeptides
NZ522844A (en) 2000-06-28 2005-02-25 Brigham & Womens Hospital PD-L2 molecules: novel PD-1 ligands and methods to identify compounds to modulate T cell activation
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
PL374463A1 (en) 2001-11-14 2005-10-17 Immunex Corporation Modulation of lir function to treat rheumatoid arthritis
WO2003052086A1 (en) 2001-12-14 2003-06-26 President And Fellows Of Harvard College Immune related neuronal receptors and therapeutic uses thereof
EP1626993B1 (en) 2003-05-09 2015-03-11 Duke University Cd20-specific antibodies and methods of employing same
WO2006122822A2 (en) * 2005-05-20 2006-11-23 Lonza Biologics Plc. High-level expression of recombinant antibody in a mammalian host cell
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
US8663634B2 (en) 2005-07-11 2014-03-04 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
CA2637786A1 (en) * 2006-01-23 2007-08-16 President And Fellows Of Harvard College Compositions and methods for enhancing neuronal plasticity and regeneration
CA2646048A1 (en) 2006-03-30 2007-11-08 Novartis Ag Compositions and methods of use for antibodies of c-met
SG10201504662WA (en) 2006-06-14 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
US7777008B2 (en) 2006-06-19 2010-08-17 Tolerx, Inc. ILT3 binding molecules and uses therefor
CN101529255A (zh) 2006-11-14 2009-09-09 健泰科生物技术公司 神经元再生的调控剂
EP2211903A4 (en) 2007-10-17 2011-07-06 Nuvelo Inc CLL-1 ANTIBODY
WO2009064944A2 (en) * 2007-11-16 2009-05-22 Nuvelo, Inc. Antibodies to lrp6
WO2009076359A2 (en) * 2007-12-11 2009-06-18 Genentech, Inc. Modulators of neuronal regeneration
CL2009001155A1 (es) 2008-05-13 2010-06-04 Genentech Inc Anticuerpo anti-pirb/lilrb aislado; polinucleotido que lo codifica; vector; celula huesped; metodo de obtencion; composicion farmaceutica que lo comprende; kit; y su uso para tratar enfermedades neurodegenerativas.
AR071777A1 (es) 2008-05-13 2010-07-14 Genentech Inc Anticuerpos contra receptor tipo inmunoglobulina de leucocitos (anti-pirb), polinucleotidos que codifican dichos anticuerpos y vectores que comprende los polinucleotidos
CN102137869B (zh) 2008-06-30 2018-07-06 宾夕法尼亚大学 Fn14/TRAIL融合蛋白
EP2406388B1 (en) 2009-03-13 2016-09-28 The Trustees Of The University Of Pennsylvania Ox40/trail fusion proteins
KR20120104517A (ko) 2009-09-03 2012-09-21 제넨테크, 인크. 류마티스 관절염의 치료, 진단 및 모니터링 방법
US8846397B2 (en) 2010-01-20 2014-09-30 Merck Sharp & Dohme Corp. Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments
US8609095B2 (en) * 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
WO2012061620A1 (en) 2010-11-04 2012-05-10 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
AR086287A1 (es) 2011-05-05 2013-12-04 Baylor Res Inst Composicion inmunoestimulante, metodo
US20150174203A1 (en) 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response

Also Published As

Publication number Publication date
US20150197570A1 (en) 2015-07-16
US9023997B2 (en) 2015-05-05
WO2011091177A1 (en) 2011-07-28
EP2525813A4 (en) 2013-07-10
US9828425B2 (en) 2017-11-28
AU2011207253A1 (en) 2012-08-16
JP2013517330A (ja) 2013-05-16
EP2525813B1 (en) 2017-01-04
AU2011207253B2 (en) 2015-02-12
EP2525813A1 (en) 2012-11-28
US20130030156A1 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
US9828425B2 (en) Anti-ILT5 antibodies and ILT5-binding antibody fragments
US9534051B2 (en) Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments
JP7673272B2 (ja) キメラ受容体及びその使用方法
US20230287120A1 (en) Dll3 targeting chimeric antigen receptors and binding agents
JP2024105337A (ja) Ｆｌｔ３に対するキメラ受容体及びその使用方法
JP7384835B2 (ja) Ｃｄ３に特異的な抗体及びその使用
JP2022513778A (ja) キメラ抗原受容体及びｔ細胞受容体並びに使用方法
TW202011999A (zh) Dll3 的嵌合受體及其使用方法
CN110035769A (zh) 针对siglec-15的抗体及其使用方法
AU2011207257B8 (en) Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments
HK40046552A (en) Antibodies specific for cd3 and uses thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20170120